Drugs / FMPV-1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05238558 | Jan → Oct 2022 | colorectal cancer | Hubro Therapeutics AS | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FMPV-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05238558 ↗ |
| Target | TGFBR2 | “FMPV-1 is designed to activate T cell responses against transforming growth factor β receptor 2 (TGFβR2) frameshift mutation.” PMID 39998682 ↗ Feb 2025 |